Beijing Northland Biotechnology Co., Ltd.
NORTHLAND Stock:BJ 920047
Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical enterprise specializing in the research, development, production and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications. Founded in June 2004 and listed on the Beijing Stock Exchange in November 2021 (stock code:920047). Northland-bio is recognized as the Key High-tech enterprise of the National Torch Program, a Beijing-based scientific research and development institution, the Beijing Naked Plasmid Gene Therapy Drug Engineering Technology Research Center, Beijing International Science and Technology Cooperation Base, Beijing G20 Innovation-Led Enterprise, and Beijing "Specialized, Rifined, Characteristic, and Innovative" SMEs.

Drug R&D
We are an innovative biopharmaceutical enterprise specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs.

Core Business
While adhering to independent research and development, we have established cooperative relationships with domestic and foreign drug research and development institutions to provide technical services and technology transfers.

Technology Platform
We have established core technology platforms for gene vector construction, engineered bacterial construction, microbial expression, mammalian cell expression, biologics production processes and large-scale production technologies, as well as eye drop drug development.

BUSINESS UNITS
Beijing Northland Biotechnology Co., Ltd.Beijing Huonland Pharmaceutical Co., Ltd.
NORTHLAND
ESG
Care for Life, Innovate and Explore, Continuous Refinement, Win-Win Cooperation.
Awards and Certificates
—We are a National High-tech enterprise,holding 22 authorized patents.We have undertaken 8 projects under the National “Major New Drug Discovery ” program.
Postdoctoral Research Workstation
Drug Manufacturing License
National High-Tech Enterprise
Beijing Specialized, Sophisticated, Distinctive and Novel SMEs
Beijing Science and Technology Research and Development Institutions
Qualifications and Honors
— A national-level high-tech enterprise with 22 authorized patents, and having undertaken 8 national-level “Major New Drug Development” projects.
Postdoctoral Research Workstation
Drug Manufacturing License
National High-Tech Enterprise
Beijing Specialized, Sophisticated, Distinctive and Novel SMEs
NORTHLAND
Investor Relations
Guided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise and making positive contributions to the advancement of China’s pharmaceutical industry and human health.



